Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)

Retina

Volumn 32, Issue 3, 2012, Pages 434-457

  Stewart, Michael W ^a   Rosenfeld, Philip J ^b   Penha, Fernando M ^b   Wang, Fenghua ^b,c   Yehoshua, Zohar ^b   Bueno Lopez, Elena ^d,e   Lopez, Pedro F ^d,e  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d BAPTIST HOSPITAL OF MIAMI   (United States)

^e FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CASE REPORT; DOSAGE SCHEDULE COMPARISON; DRUG BINDING; DRUG DOSE COMPARISON; DRUG HALF LIFE; FEMALE; HUMAN; MATHEMATICAL MODEL; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT PLANNING;

EID: 85027955048     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0B013E31822C290F     Document Type: Article

References (28)

1. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009;20:158-165.
2. Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol 2009;20:166-174.
3. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service Part B claims file. Am J Ophthalmol 2011;151:887-895.
4. Schmidt-Erfurth U, Pollreisz A, Mitsch C, Bolz M. Antivascular endothelial growth factors in age-related macular degeneration. Dev Ophthalmol 2010;46:21-38.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
6. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
7. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65; e5.
8. Schouten JS, La Heij EC, Webers CA, et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247:1-11.
9. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology 2010;117: 298-302.
10. Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye (Lond) 2010;24: 816-824.
11. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58; e1.
12. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
13. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134-2140.
14. Comparison of Age-Related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial Available at: http://www.clinicaltrials. gov/ct2/show/NCT00593450?term=catt&rank=1. Accessed December 28, 2010.
15. Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase iii ranibizumab clinical trials. Ophthalmology 2011;118:523-530.
16. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-1053. (Pubitemid 40797460)
17. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:642; e1-e4.
18. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:623-632.
19. A Study of Ranibizumab Administered Monthly or on an As-Needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (HARBOR) Available at: http://www.clinicaltrials.gov/ct2/show/NCT00891735?term= harbor&rank=1. Accessed December 28, 2010.
20. Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 1) Available at: http://www.clinicaltrials. gov/ct2/show/study/NCT00509795?term= VEGF+ Trap+VIEW&rank=1&show-locs=Y#locn. Accessed December 28, 2010.
21. Stewart MW. Predicted biologic activity of intravitreal bevacizumab. Retina 2007;27:1196-1200. (Pubitemid 350211524)
22. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92: 667-668. (Pubitemid 351684178)
23. Funk M, Karl D, Georgopoulos M, et al. Neovascular agerelated macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116:2393-2399.
24. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008;115:1750-1755; e1.
25. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025-1032.
26. Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-Related Macular Degeneration Available at: http://newsroom.regeneron. com/releasedetail.cfm?ReleaseID=532099&rank= 1&show-locs=Y#locn. Accessed December 28, 2010.
27. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular agerelated macular degeneration. Am J Ophthalmol 2007;143: 566-583.
28. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508-512.